Qiagen Collaborates with Institut Curie to Develop High-Throughput RNAi Tools
News Oct 13, 2005
Qiagen and Institut Curie have announced a collaboration to develop tools for high-throughput RNAi screening as part of the Institut Curie BioPhenics project.
This project, led by Drs Jacques Camonis and Franck Perez, aims to use RNAi technology in conjunction with advanced systematic phenotypic analysis to accelerate cancer drug discovery.
“As one of the largest cancer research centers in Europe, part of the ongoing research at Institut Curie is dedicated to the understanding of how cells become cancerous,” said Jacques Camonis, head of the BioPhenics project in the Translational Department at Institut Curie.
“The goal of the 'BioPhenics' project is to apply cell biology and microscopic imaging to cancer research for a deeper understanding, improved target validation and, ultimately, more efficient cancer drug discovery.”
“Qiagen is pleased to be able to contribute to this ambitious and exciting research,” said Jie Kang, V.P. of R & D at Qiagen.
“The combination of Qiagen advanced siRNA design and extremely efficient HiPerFect delivery reagent should contribute greatly to the overall goals of the project.”
In a new study in cells, University of Illinois researchers have adapted CRISPR gene-editing technology to cause the cell’s internal machinery to skip over a small portion of a gene when transcribing it into a template for protein building. This gives researchers a way not only to eliminate a mutated gene sequence, but to influence how the gene is expressed and regulated.
Researchers published today a detailed description of the complete genome of bread wheat, the world's most widely-cultivated crop. This work will pave the way for the production of wheat varieties better adapted to climate challenges, with higher yields, enhanced nutritional quality and improved sustainability.